ABUNDANCE INTERNATIONAL LIMITED
沣裕国际有限公司
(Singapore Co. Reg. No: 197501572K)

NEWS RELEASE - FOR IMMEDIATE RELEASE
Results for half year ended 30 June 2026

	1H2026	**1H2025**	Increase/(Decrease)	
	US$ million	US$ million	US$ million	%
Revenue	150.9	258.4	(107.5)	(41.6)
Earnings/(Losses) before interest, taxation, depreciation and amortisation (“**EBITDA/(LBITDA)**”)	2.4	(0.5)	2.9	N.M.*
Profit/(Loss) after tax for the period	1.3	(1.1)	2.4	N.M.*

**N.M.: Not Meaningful*

Singapore, 7 August 2026 – SGX Catalist-listed Abundance International Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) today announced its results for the half year ended 30 June 2026 (“**1H2026**”).

Comparing 1H2026 to the half year ended 30 June 2025 (“**1H2025**”):

- Revenue decreased by US$107.5 million to US$150.9 million from US$258.4 million
- EBITDA of US$2.4 million up by US$2.9 million from LBITDA of US$0.5 million
- Profit after tax of US$1.3 million, improving by US$2.4 million from a loss after tax of US$1.1 million

The decrease in revenue was mainly due to continued softness in customer demand, particularly the PRC market during 1H2026, amid ongoing global economic uncertainty.

Managing Director, Mr Sam Kok Yin said, “Our main markets remain weak and still facing an oversupply situation. As a company, we have to adapt accordingly. Our cost rationalisation efforts and stricter inventory and management control have allowed us to turn in a profit for this half year as compared to a loss in the preceding one, and we will continue to exercise prudence going ahead.”

Mr Sam added, "Separately, as announced on 13 March 2026 and 2 June 2026, the Company's wholly owned subsidiary, Abundance Specialty Chemicals Pte Ltd ("**ASCPL**"), has signed a licensing agreement with Molecular Targeting Technologies, Inc. ASCPL has on 1 June 2026 incorporated a wholly-owned subsidiary, Abundance Biomedical (Shanghai) Co., Ltd., as part of the Group's strategic initiative for the commercialisation and production of CypH-11 in the PRC.

We will continue to explore and evaluate other chemical related investment opportunities, striking a balance between long- and short-term investments. We will also seek appropriate exits for our investments when the time is right."

………. End ……….

About Abundance International Limited

Incorporated in Singapore in 1975 and listed on SGX Sesdaq in 2000, the Company (previously known as Craft Print International Limited) was engaged primarily in the business of commercial printing of books, calendars and other publications. In 2015, it diversified its business scope and today, the Company's businesses comprise Chemicals, Investments and Print and Paper Management.

For further information, please email to: contact@abundance.com.sg or call +65 6861 4040.

Note:

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.